QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorQilu Pharmaceutical Co., Ltd.
About this trial
This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.
Eligibility criteria
Qualifiers
Aged 18-80 years (inclusive)
Participants diagnosed with heterozygous familial hypercholesterolemia by Dutch Lipid Clinic
Network criteria or genetic testing;
Serum low density lipoprotein cholesterol ≥2.6 millimoles (mmol)/liter (L) at screening.
Disqualifiers
New York Heart Association (NYHA) class III or IV heart failure.
Uncontrolled cardiac arrhythmia.
Cardiovascular Diseases within 3 months.
Uncontrolled hypertension.
Trial design
Treatments tested in this trial
- QLC7401 Injection
- Placebo
Treatment groups
120 Participants
are divided into 2 treatment groupsLocations
This trial has no locations
Sponsors and collaborators
Qilu Pharmaceutical Co., Ltd.
Lead sponsor
Source ClinicalTrials.gov